Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients

ClinicalTrials.gov ID: NCT00001022

Public ClinicalTrials.gov record NCT00001022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Comparative Trial of Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus Dideoxycytidine (ddC) in HIV-Infected Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary: To compare the efficacy of zidovudine ( AZT ) given alone versus AZT plus didanosine ( ddI ) versus AZT plus zalcitabine ( dideoxycytidine; ddC ) in delaying the occurrence of AIDS-related conditions in HIV-infected patients. Secondary: To compare the frequency and severity of adverse experiences in the three regimens. To compare the mortality rates in the three regimens. To compare the effects of antiretroviral regimens on CD4+ cell levels. Studies have indicated that maintenance therapy with AZT over extended periods may be limited by dose-dependent toxicity, primarily myelosuppression, and by the emergence of drug-resistant HIV strains. It is anticipated that the combination of AZT with either ddI or ddC may promote higher antiviral efficacy, with acceptable toxicity and less likelihood of development of drug-resistant strains, than AZT alone.

Study identification

NCT ID
NCT00001022
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
1,200 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Nov 30, 1995
Last update posted
Nov 3, 2021

Ends 1995

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
14
Facility City State ZIP Site status
Community Consortium of San Francisco San Francisco California 94110
Denver CPCRA / Denver Public Hlth Denver Colorado 80204
Hill Health Corp New Haven Connecticut 06519
Wilmington Hosp / Med Ctr of Delaware Wilmington Delaware 19899
Veterans Administration Med Ctr / Regional AIDS Program Washington D.C. District of Columbia 20422
AIDS Research Consortium of Atlanta Atlanta Georgia 30308
AIDS Research Alliance - Chicago Chicago Illinois 60657
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med New Orleans Louisiana 70112
Comprehensive AIDS Alliance of Detroit Detroit Michigan 48201
Henry Ford Hosp Detroit Michigan 48202
North Jersey Community Research Initiative Newark New Jersey 07103
Addiction Research and Treatment Corp Brooklyn New York 11201
Clinical Directors Network of Region II New York New York 10011
Harlem AIDS Treatment Group / Harlem Hosp Ctr New York New York 10037
Portland Veterans Adm Med Ctr / Rsch & Education Grp Portland Oregon 97210
Richmond AIDS Consortium Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00001022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2021 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00001022 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →